Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Jorge A. CARRASQUILLO 1, 2, Patrick G. MORRIS 3, 4, John L. HUMM 5, Peter M. SMITH-JONES 1, 6, Volkan BEYLERGIL 1, Timothy AKHURST 1, 7, Joseph A. O'DONOGHUE 5, Shutian RUAN 1, Shanu MODI 3, Clifford A. HUDIS 3, Steven M. LARSON 1, 2, 8
1 Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, US; 2 Center for Radioimmunotherapy and Theranostics at Ludwig Center at MSK; 3 Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US; 4 Currently at the Department of Oncology, Beaumont Hospital, Dublin, Ireland; 5 Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, US; 6 Currently at the Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA; 7 Currently at the Peter MacCallum Cancer Centre, Melbourne, Australia; 8 Sloan Kettering Institute, New York, NY, USA
BACKGROUND: The current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu)-trastuzumab.
METHODS: An i.v. injection of 296-370MBq/5mg 64Cu-trastuzumab was administered between 1 to 4 h after routine trastuzumab treatment. Whole-body PET scans were performed immediately post-injection and at 24 h post-injection. Serial pharmacokinetics were performed. Of 11 patients (median age of 52; range of 31-61), 8 underwent a repeat study with 64Cu-trastuzumab to assess image and pharmacokinetic reproducibility. Patients were monitored for toxicity.
RESULTS: Patients experienced no allergic reactions or significant adverse effects from 64Cu- trastuzumab. Eight patients successfully completed a repeat 64Cu-trastuzumab study, with acceptable reproducibility of both the biodistribution and pharmacokinetic clearance. Study 1 vs. study 2 showed similar serum concentration post-injection (mean 42.4 + 7.8 %ID/L vs. 44.7 + 12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 h), p>0.5. The volume of distribution (median 2.50L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60L. Of 11 patients, 2 had 64Cu-trastuzumab localization corresponding to known tumor sites—1 in liver and 1 in breast.
CONCLUSIONS: Preliminary results suggest that scanning with 64Cu-trastuzumab is feasible, safe, and reproducible. Tumor uptake of 64Cu-trastuzumab was observed, but tumor detection exhibited low sensitivity in this study in which imaging was performed in the presence of trastuzumab therapy.